LRP1调控Aβ代谢的机制及其对AD防治研究的启示  

Mechanisms of low density lipoprotein receptor related protein 1 regulatingβ-amyloid metabolism and its implications for prevention and treatment of Alzheimer's disease in the future

作　　者：张君臣 徐武华[2] Zhang Junchen;Xu Wuhua(Clinical School of Medicine,Guizhou Medical University,Guiyang 550004,China;Department of Rehabilitation Medicine(Neurology II),Guangzhou Red-Cross Hospital,Guangzhou Institute of Disease-oriented Nutritional Research,Medical School,Jinan University,Guangzhou 510220,China)

机构地区：[1]贵州医科大学临床医学院,贵阳550004 [2]暨南大学医学院附属广州红十字会医院康复医学科(神经内科二区),暨南大学医学院广州疾病营养研究所,广州510220

出　　处：《中华神经医学杂志》2019年第12期1289-1293,共5页Chinese Journal of Neuromedicine

基　　金：广东省自然科学基金(S201210008985);广州市科技计划项目(201604020100)。

摘　　要：目前,诸多以免疫清除脑内β-淀粉样蛋白(Aβ)斑块为标靶的阿尔茨海默病(AD)免疫治疗研究因均未达到预期的临床效果而陷入空前的困境。近年来研究表明,低密度脂蛋白受体相关蛋白1(LRP1)可通过多种途径参与Aβ的生成及非免疫清除,从而显示出一种异于经典Aβ免疫治疗的干预靶点潜质。为此,笔者现重点阐述LRP1在生理及AD状态下Aβ代谢过程中的作用,并展望其作为一种全新干预靶点在未来AD防治中的应用前景。Almost all active immunotherapy attempts which targeted at clearing or reducingβ-amyloid(Aβ)plaques in brains of patients with Alzheimer'disease(AD)were fallen into unprecedented difficulties,because of unsatisfactory curative effects.Recently,more and more evidences support that low density lipoprotein receptor related protein 1(LRP1)is involved in Aβproduction and clearance through multiple non-immune pathways,which has showed the potential as a whole-new interference target different with classical Aβimmunotherapies.So,we try to summarize the research developments of roles of LRP1 in Aβmetabolic process in physiological and AD conditions,and look forward to its possible applications in the prevention and treatment of AD.

关 键 词：阿尔茨海默病 低密度脂蛋白受体相关蛋白1 β-淀粉样蛋白代谢 

分 类 号：R74[医药卫生—神经病学与精神病学]